Strategic partnerships Leverage existing collaboration with academic, private, and NIH networks to identify co-development and contract research opportunities in vaccines, therapeutics, and diagnostic imaging, expanding outreach to potential grant-funded programs and sponsored trials.

SBIR and funding Position Molecular Express as a partner for government-funded initiatives by highlighting past SBIR Phase I/II engagements to win new funding-backed projects, particularly in adjuvants, lung surfactants, and related life science innovations.

Focused capabilities Target opportunities in small molecule drugs and proteins for vaccines and therapeutics, while also exploring adjacent markets like cannabis-infused cosmetics and contrast agents, to broaden project scope with shared manufacturing and formulation expertise.

Health market relevance Emphasize expertise in respiratory care and immune system applications to align with hospitals, research institutions, and biotech firms seeking solutions for acute lung injury, ARDS, and imaging contrast, leveraging existing reputational cues.

Mid-market positioning Capitalize on the company’s mid-size profile (11-50 employees) to win agile, cost-effective partnerships that require rapid R&D iterations, personalized service, and flexible collaboration compared to larger competitors.